Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0978 | 0.5 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.0978 | 0.5 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0978 | 0.5 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.0978 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0978 | 0.5 | 0.5 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0978 | 0.5 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase | 0.0978 | 0.5 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.0978 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0978 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0978 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0978 | 0.5 | 0.5 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0978 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0978 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0978 | 0.5 | 0.5 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.0978 | 0.5 | 0.5 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0978 | 0.5 | 0.5 |
Trypanosoma brucei | protein kinase, putative | 0.0978 | 0.5 | 0.5 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0978 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0978 | 0.5 | 0.5 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0978 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 52.21 % | Analgesic activity in Mus musculus Swiss albino (mouse) assessed as protection against acetic acid-induced writhing response at 20 mg/kg, po administered 30 min before acetic acid challenge measured at 0.5 hr after challenge | ChEMBL. | No reference |
Activity (functional) | = 56.5 % | Analgesic activity in Mus musculus Swiss albino (mouse) assessed as protection against acetic acid-induced writhing response at 20 mg/kg, po administered 30 min before acetic acid challenge measured at 2 hr after challenge | ChEMBL. | No reference |
Activity (functional) | = 60.58 % | Analgesic activity in Mus musculus Swiss albino (mouse) assessed as protection against acetic acid-induced writhing response at 20 mg/kg, po administered 30 min before acetic acid challenge measured at 1 hr after challenge | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.